10.12.2023, 2895 Zeichen

OMV: Tthe Executive Board of oil, gas and chemicals group OMV has decided to enter into negotiations with interested bidders on the commercial terms and the contractual documentation for the potential sale of 50% of the shares in SapuraOMV Upstream Sdn. Bhd. In the event of a sale, OMV expects, based on the offers received by such bidders so far, a total consideration in the high three-digit million (USD) range. Furthermore, the Executive Board of OMV has decided today, to continue the ongoing sales process for 100% of the shares in OMV New Zealand Limited separately, as there was limited interested in a combined deal.
OMV: weekly performance: -1.45%

Agrana: The Supervisory Board of Agrana Beteiligungs-AG appointed Stephan Büttner, as Chief Executive Officer of Agrana Beteiligungs-AG with effect from 1 January 2024.Büttner succeeds Markus Mühleisen, who has decided not to extend his Management Board mandate beyond 31 May 2024. Mühleisen will leave the Management Board of Agrana Beteiligungs-AG at his own request, effective 31 December 2023. As the new CEO of Agrana Beteiligungs-AG, Stephan Büttner will be responsible for Strategy & Business Policy, Sales, Public Relations, Human Resources and Corporate Secretariat, in addition to his existing responsibilities as the Group’s Chief Financial Officer and CEO of the Fruit segment.
Agrana: weekly performance: 0.00%

Valneva: Pfizer and Valneva SE announced that they have completed recruitment for the Phase 3 trial Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524) for Lyme disease vaccine candidate VLA15. The trial builds on previous positive Phase 1 and 2 trial results and includes both adult and pediatric participants, with the aim to confirm the efficacy, safety, lot consistency, and immunogenicity of VLA15. Annaliesa Anderson, Senior Vice President and Head Vaccine Research and Development, Pfizer: “If approved, a vaccine could prevent the disease and ease the burden of acute, severe and sometimes persistent consequences in both adults and children. We look forward to progressing the trial with the goal of submitting a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) and Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in 2026, subject to positive data.”
Valneva: weekly performance: -1.16%

Kontron: IoT technology group Kontron announced the signing of a contract exceeding EUR 30m for fiber optic solutions. The new client is a significant player in the telecommunications sector in Germany. Kontron’s Slovenian subsidiary for broadband solutions will support the Telco operator with cutting-edge server systems and software for the operation and optimization of the optical broadband rollout in Germany.
Kontron: weekly performance: 4.22%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (05/12/2023)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #809: Post-Xmas-Boom bei Aktien von Pierer Mobilty, AT&S, Porr, UBM und Palfinger; Infos zum Jahresendhandel

Bildnachweis

Aktien auf dem Radar:Pierer Mobility, Warimpex, RHI Magnesita, Immofinanz, Addiko Bank, CA Immo, Mayr-Melnhof, Verbund, ATX, ATX Prime, ATX TR, Wienerberger, Kostad, EVN, Lenzing, Österreichische Post, Strabag, Athos Immobilien, AT&S, Cleen Energy, Marinomed Biotech, RWT AG, SBO, UBM, Agrana, Amag, Flughafen Wien, OMV, Palfinger, Telekom Austria, Uniqa.

---